Efficacy of peroxisome proliferator activated receptor agonist in the treatment of virus-associated haemophagocytic syndrome in a rabbit model

Chuang H.C. , Lay J.D. , Hsieh W.C. , Su I.J. Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: nuclear factor-kappa B pathway as a potential therapeutic target. Cancer Sci 2007; 98: 1281–1287.

Ishii E. , Ohga S. , Imashuku S. Review of hemophagocytic lymphohistiocytosis (HLH) in children with focus on Japanese experiences. Crit Rev Oncol Hematol 2005; 53: 209–223.

Cheung C.Y. , Poon L.L. , Lau A.S. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002; 360: 1831–1837.

To K.F. , Chan P.K. , Chan K.F. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol 2001; 63: 242–246.

Larroche C. , Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun Rev 2004; 3: 69–75.

Su I.J. Perspectives on the pathogenesis and therapy of hemophagocytic syndrome. J Formos Med Assoc 2008; 107: 277–280.

Lay J.D. , Chuang S.E. , Rowe M. , Su I.J. Epstein-barr virus latent membrane protein-1 mediates upregulation of tumor necrosis factor-alpha in EBV-infected T cells: implications for the pathogenesis of hemophagocytic syndrome. J Biomed Sci 2003; 10: 146–155.

Lay J.D. , Tsao C.J. , Chen J.Y. , Kadin M.E. , Su I.J. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest 1997; 100: 1969–1979.

Chuang H.C. , Lay J.D. , Hsieh W.C. Epstein-Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the pathogenesis of hemophagocytic syndrome. Blood 2005; 106: 3090–3096.

Henter J.I. Biology and treatment of familial hemophagocytic lymphohistiocytosis: importance of perforin in lymphocyte-mediated cytotoxicity and triggering of apoptosis. Med Pediatr Oncol 2002; 38: 305–309.

Willson T.M. , Lambert M.H. , Kliewer S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001; 70: 341–367.

Belfort R. , Harrison S.A. , Brown K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297–2307.

Ricote M. , Li A.C. , Willson T.M. , Kelly C.J. , Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79–82.

Jiang C. , Ting A.T. , Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82–86.

Yang X.Y. , Wang L.H. , Chen T. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 2000; 275: 4541–4544.

Appel S. , Mirakaj V. , Bringmann A. , Weck M.M. , Grunebach F. , Brossart P. PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways. Blood 2005; 106: 3888–3894.

Skolnik P.R. , Rabbi M.F. , Mathys J.M. , Greenberg A.S. Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects. J Acquir Immune Defic Syndr 2002; 31: 1–10.

Arnold R. , Konig W. Peroxisome-proliferator-activated receptor-gamma agonists inhibit the release of proinflammatory cytokines from RSV-infected epithelial cells. Virology 2006; 346: 427–439.

Hayashi K. , Ohara N. , Teramoto N. An animal model for human EBV-associated hemophagocytic syndrome: herpesvirus papio frequently induces fatal lymphoproliferative disorders with hemophagocytic syndrome in rabbits. Am J Pathol 2001; 158: 1533–1542.

Hayashi K. , Teramoto N. , Akagi T. Animal in vivo models of EBV-associated lymphoproliferative diseases: special references to rabbit models. Histol Histopathol 2002; 17: 1293–1310.

Lee Y.S. , Tanaka A. , Lau R.Y. , Nonoyama M. , Rabin H. Comparative studies of herpesvirus papio (baboon herpesvirus) DNA and Epstein-Barr virus DNA. J Gen Virol 1980; 51: 245–253.

Hsieh W.C. , Chang Y. , Hsu M.C. Emergence of anti-red blood cell antibodies triggers red cell phagocytosis by activated macrophages in a rabbit model of Epstein-Barr virus-associated hemophagocytic syndrome. Am J Pathol 2007; 170: 1629–1639.

Neuschwander-Tetri B.A. , Brunt E.M. , Wehmeier K.R. , Oliver D. , Bacon B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008–1017.

Promrat K. , Lutchman G. , Uwaifo G.I. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188–196.

Evans R.M. , Barish G.D. , Wang Y.X. PPARs and the complex journey to obesity. Nat Med 2004; 10: 355–361.

Farrell G.C. , Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99–S112.

Na H.K. , Surh Y.J. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation. Biochem Pharmacol 2003; 66: 1381–1391.

Cuzzocrea S. , Pisano B. , Dugo L. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 2004; 483: 79–93.

Mueller E. , Smith M. , Sarraf P. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A 2000; 97: 10990–10995.

Lu J. , Imamura K. , Nomura S. Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Res 2005; 65: 4769–4774.

Kassouf W. , Chintharlapalli S. , Abdelrahim M. , Nelkin G. , Safe S. , Kamat A.M. Inhibition of bladder tumor growth by 1,1-bis(3’-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res 2006; 66: 412–418.

Jung Y.J. , Isaacs J.S. , Lee S. , Trepel J. , Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003; 17: 2115–2117.

Genolet R. , Wahli W. , Michalik L. PPARs as drug targets to modulate inflammatory responses? Curr Drug Targets Infamm Allergy 2004; 3: 361–375.

Sun X.F. , Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol 2007; 22: 1387–1398.

Terblanche M. , Almog Y. , Rosenson R.S. , Smith T.S. , Hackam D.G. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007; 7: 358–368.

Merx M.W. , Liehn E.A. , Graf J. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005; 112: 117–124.

Merx M.W. , Liehn E.A. , Janssens U. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004; 109: 2560–2565.

Mishra S. , Mishra J.P. , Kumar A. Activation of JNK-dependent pathway is required for HIV viral protein R-induced apoptosis in human monocytic cells: involvement of antiapoptotic BCL2 and c-IAP1 genes. J Biol Chem 2007; 282: 4288–4300.

Trujillo-Murillo K. , Rincon-Sanchez A.R. , Martinez-Rodriguez H. Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. Hepatology 2008; 47: 1462–1472.

Chang W.W. , Su I.J. , Chang W.T. , Huang W. , Lei H.Y. Suppression of p38 mitogen-activated protein kinase inhibits hepatitis B virus replication in human hepatoma cell: the antiviral role of nitric oxide. J Viral Hepat 2008; 15: 490–497.

de Jong M.D. , Simmons C.P. , Thanh T.T. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12: 1203–1207.